Latest filings (excl ownership)
8-K
Replimune Announces Appointment of Sushil Patel to CEO and Executive Leadership Transitions
26 Mar 24
10-Q
2024 Q3
Quarterly report
8 Feb 24
8-K
Replimune Reports Fiscal Third Quarter 2024 Financial Results and Provides Corporate Update
8 Feb 24
8-K
Regulation FD Disclosure
8 Jan 24
8-K
Entry into a Material Definitive Agreement
26 Dec 23
8-K
Other Events
5 Dec 23
10-Q
2024 Q2
Quarterly report
7 Nov 23
8-K
Replimune Reports Fiscal Second Quarter 2024 Financial Results and Provides Corporate Update
7 Nov 23
8-K
Replimune Announces Appointment of Emily Hill as Chief Financial Officer
19 Sep 23
8-K
Submission of Matters to a Vote of Security Holders
7 Sep 23
8-K
Entry into a Material Definitive Agreement
3 Aug 23
S-3ASR
Automatic shelf registration
3 Aug 23
10-Q
2024 Q1
Quarterly report
3 Aug 23
8-K
Replimune Reports Fiscal First Quarter 2024 Financial Results and Provides Corporate Update
3 Aug 23
ARS
2023 FY
Annual report to shareholders
26 Jul 23
DEFA14A
Additional proxy soliciting materials
26 Jul 23
DEF 14A
Definitive proxy
26 Jul 23
8-K
Replimune Announces Sander Slootweg will Depart from its Board of Directors
20 Jul 23
8-K
Replimune Appoints Veleka R. Peeples-Dyer to its Board of Directors
5 Jun 23
S-8
Registration of securities for employees
18 May 23
10-K
2023 FY
Annual report
18 May 23
8-K
Replimune Reports Fiscal Fourth Quarter and Year Ended 2023 Financial Results and Provides Corporate Update
18 May 23
8-K
Regulation FD Disclosure
27 Feb 23
10-Q
2023 Q3
Quarterly report
9 Feb 23
8-K
Replimune Reports Fiscal Third Quarter Financial Results and Provides Corporate Update
9 Feb 23
8-K
Replimune Appoints Former Sanofi U.S. Commercial Oncology Head, Chris Sarchi, as Chief Commercial Officer and Sushil Patel as Chief Strategy Officer
4 Jan 23
8-K
Replimune Announces Proposed Public Offering
12 Dec 22
424B5
Prospectus supplement for primary offering
12 Dec 22
424B5
Prospectus supplement for primary offering
7 Dec 22
8-K
Replimune Enters into Clinical Collaboration Agreement with Roche for the Development of RP3 In Colorectal Cancer and Hepatocellular Carcinoma
7 Dec 22
10-Q
2023 Q2
Quarterly report
3 Nov 22
8-K
Replimune Reports Fiscal Second Quarter Financial Results and Provides Corporate Update
3 Nov 22
8-K
Entry into a Material Definitive Agreement
7 Oct 22
8-K
Submission of Matters to a Vote of Security Holders
8 Sep 22
10-Q
2023 Q1
Quarterly report
4 Aug 22
8-K
Replimune Reports Fiscal First Quarter Financial Results and Provides Corporate Update
4 Aug 22
EFFECT
Notice of effectiveness
28 Jul 22
DEFA14A
Additional proxy soliciting materials
27 Jul 22
DEF 14A
Definitive proxy
27 Jul 22
CORRESP
Correspondence with SEC
27 Jul 22
Latest ownership filings
SC 13G/A
PRICE T ROWE ASSOCIATES INC /MD/
10 Apr 24
SC 13G/A
STATE STREET CORP
10 Apr 24
4
Veleka Peeples-Dyer
3 Apr 24
4
Sushil Patel
3 Apr 24
4
Paolo Pucci
3 Apr 24
4
Konstantinos Xynos
3 Apr 24
4
Kapil Dhingra
3 Apr 24
4
Emily Luisa Hill
3 Apr 24
4
Christopher Sarchi
3 Apr 24
4
JOSEPH P SLATTERY
3 Apr 24
4
Dieter Weinand
3 Apr 24
4
Christy J. Oliger
3 Apr 24
4
Hyam Levitsky
3 Apr 24
4
Andrew Schwendenman
3 Apr 24
SC 13G/A
Omega Fund IV, L.P.
14 Feb 24
SC 13G/A
Redmile Group, LLC
14 Feb 24
SC 13G/A
PRICE T ROWE ASSOCIATES INC /MD/
14 Feb 24
SC 13G/A
Forbion Capital Fund III Cooperatief U.A.
14 Feb 24
SC 13G
MORGAN STANLEY
9 Feb 24
SC 13G/A
BlackRock Inc.
26 Jan 24
SC 13G
STATE STREET CORP
25 Jan 24
SC 13G/A
BAKER BROS. ADVISORS LP
10 Jan 24
4
Konstantinos Xynos
17 Nov 23
4
Christopher Sarchi
17 Nov 23
4
Emily Luisa Hill
20 Sep 23
3
Emily Luisa Hill
20 Sep 23
4
Pamela Esposito
13 Sep 23
4
Pamela Esposito
24 Aug 23
4
Pamela Esposito
15 Aug 23
3
Christopher Sarchi
26 Jul 23
4
Pamela Esposito
11 Jul 23
144
Notice of proposed sale of securities
10 Jul 23
4
Tanya Lewis
15 Jun 23
4
Sushil Patel
15 Jun 23
144
Notice of proposed sale of securities
13 Jun 23
144
Notice of proposed sale of securities
13 Jun 23
4
Veleka Peeples-Dyer
5 Jun 23
3
Veleka Peeples-Dyer
5 Jun 23
3
Andrew Schwendenman
18 May 23
4
Sushil Patel
18 May 23